Although several covalent KRAS G12C inhibitors have made great progress in the treatment
of KRAS G12C-mutant cancer, their clinical applications are limited by adaptive resistance …

D‐1553 is a small molecule inhibitor selectively targeting KRASG12C and currently in phase
II clinical trials. Here, we report the preclinical data demonstrating antitumor activity of D …

Kirsten rats sarcoma viral oncogene (KRAS), the first discovered human oncogene, has long
been recognized as “undruggable”. KRAS mutations frequently occur in multiple human …

Despite decades of research, efforts to directly target KRAS have been challenging.
MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that …

Background KRAS is mutated in∼ 90% of pancreatic ductal adenocarcinomas,∼ 35% of
colorectal cancers and∼ 20% of non-small-cell lung cancers. There has been recent …

Background: Mutations in KRAS are among the most common aberrations in cancer.
However, despite considerable research efforts, KRAS remains a challenging therapeutic …

The role of KRAS, when activated through canonical mutations, has been well established in
cancer. Here we explore a secondary means of KRAS activation in cancer: focal high-level …

Mutational activation of KRAS is a common event in human tumors. Identification of the key
signaling pathways downstream of mutant KRAS is essential for our understanding of how to …

KRAS is one of the most frequently mutated oncogenes in human cancer. Despite
substantial efforts, no clinically applicable strategy has yet been developed to effectively …

No effective targeted therapies exist for cancers with somatic KRAS mutations. Here we
develop a synthetic lethal chemical screen in isogenic KRAS-mutant and wild-type cells to …